SuperworthImmuneering EPS IMRX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$1.04
- Latest quarter, Q2 FY26
- −$0.27
- Fiscal year 2025
- −$1.38
Immuneering's earnings per share was −$1.04 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.27.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.38 | n/a |
| FY2024 | −$2.03 | n/a |
| FY2023 | −$1.89 | n/a |
| FY2022 | −$1.92 | n/a |
| FY2021 | −$3.76 | n/a |
| FY2020 | −$3.45 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.27 | n/a | −$1.04 | |
| Q1 FY26 | −$0.21 | n/a | −$1.17 | |
| Q4 FY25 | −$0.18 | n/a | −$1.38 | |
| Q3 FY25 | −$0.38 | n/a | −$1.78 | |
| Q2 FY25 | −$0.40 | n/a | −$1.89 | |
| Q1 FY25 | −$0.42 | n/a | −$1.96 | |
| Q4 FY24 | −$0.58 | n/a | −$2.03 | |
| Q3 FY24 | −$0.49 | n/a | −$1.97 | |
| Q2 FY24 | −$0.47 | n/a | −$1.91 | |
| Q1 FY24 | −$0.49 | n/a | −$1.87 | |
| Q4 FY23 | −$0.52 | n/a | −$1.89 | |
| Q3 FY23 | −$0.43 | n/a | −$1.87 |
Against its peers
Companies in Drug Manufacturers - General nearest Immuneering's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IMRXImmuneering | −$1.04 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| ABUSArbutus Biopharma | $0.78 | |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Immuneering
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.